This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quest Diagnostics To Acquire Lab-Related Clinical Outreach Operations Of Dignity Health In California And Nevada

MADISON, N.J. and SAN FRANCISCO, April 17, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has entered into a definitive agreement to acquire lab-related clinical outreach service operations of Dignity Health, a hospital system based in California.

Under the agreement, Quest Diagnostics will acquire operations through which Dignity Health currently provides outreach diagnostic information services to patients and physician offices in parts of California and Nevada. Outreach services are provided by hospitals to physicians and patients outside of a hospital setting. Dignity Health's hospital-based laboratories are not included in the sale. Quest Diagnostics will perform testing from the acquired operations through its clinical laboratories in West Hills and Sacramento, Calif., and Las Vegas, Nevada.

The transaction is expected to be completed in June 2013, assuming customary approvals. Additional terms were not disclosed.

"With this acquisition, patients, physicians and payers in California and Nevada will gain access to a wider range of high-quality, innovative diagnostic information services and patient service center options at lower cost," said Steve Rusckowski, president and chief executive officer, Quest Diagnostics. "In addition, this acquisition is consistent with our five-point strategy, which includes delivering disciplined capital deployment and driving one to two percent in growth per year through strategically aligned fold-in acquisitions."

Quest Diagnostics expects the transaction to be neutral to adjusted earnings in 2013 and modestly accretive to earnings per share in 2014. The company also expects it to contribute about half a percentage point to consolidated revenues annually. 

"This agreement will provide patients and physicians with continued access to high-quality, cost effective diagnostic information services through Quest Diagnostics," said Lloyd Dean, president/CEO of Dignity Health. "Quest's specialization in diagnostic information services will enable this important service line to remain competitive while also allowing Dignity Health to invest more strategically in acute and ambulatory clinical care."

Assuming its completion, the transaction will be the second acquisition by Quest Diagnostics of an outreach business in 2013. In January 2013, Quest Diagnostics acquired the clinical and anatomic-pathology outreach laboratory businesses of Massachusetts-based UMass Memorial Medical Center, a member of UMass Memorial Health Care.

"Our agreement with Dignity Health underscores the attractiveness of Quest Diagnostics as a provider of low-cost, high-quality diagnostic information services to hospital systems which, in light of health care reform and growing reimbursement pressures, are considering strategic alternatives for their lab outreach businesses," said Rusckowski.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,641.77 +169.40 1.03%
S&P 500 1,975.40 +24.04 1.23%
NASDAQ 4,759.2910 +51.5160 1.09%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs